QP104-25 Commercial Pharmacy Benefit Exclusion for Azmiro™, Ospomyv™, Starjemza™, Vistaseal™ kit, and Weed Mix Number 7B

QP103-25 PCA Agency and Community First Services and Supports Requirements

QP102-25 Prior Authorization and Notification Process for Early Intensive Behavioral Intervention (EIBI)/Early Intensive Developmental and Behavioral Intervention (EIDBI)

2026 Group Medicare Advantage Value Formulary

For Group Medicare Advantage Classic Rx 1 and Value Rx 4 (PPO) plans

2026 Medicare Advantage Metro Comfort Evidence of Coverage

2026 MAPD Metro Comfort Evidence of Coverage

Program effective Date: Dec 10, 2025

This document is temporarily unavailable. Try again later.

QP107-25 Commercial Pharmacy Benefit Exclusion for Select Medications

QP45-25 Multiple Medicaid Coverages Listed on the Same Claim

QP64-25 Commercial Pharmacy Benefit Exclusion for Enflonsia™, Imuldosa™, Osenvelt®, Stoboclo®, Yeztugo® and Zusduri™

QP69-25 Update on PAC Authorization Submission Process, Effective August 1, 2025